Abstract: The present invention provides: a prophylactic or therapeutic agent for at least one type of cancer selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma and liver cancer; a prophylactic or therapeutic agent for the aforementioned cancer, which is used in a combination drug in combination with the aforementioned agent; a combination drug comprising the aforementioned agents; and a method for screening for a prophylactic or therapeutic agent for at least one type of cancer selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma and liver cancer. Provided is a prophylactic or therapeutic agent for at least one type of cancer selected from the group consisting of pancreatic cancer, lung cancer, colorectal cancer, cholangiocarcinoma and liver cancer, the agent comprising a substance capable of reducing the expression of MEX3B gene or MEX3B protein or a substance capable of inhibiting MEX3B protein.

Abstract: Provided are a nucleic acid with improved ability to inhibit the expression of the MEX3B gene with low occurrence of cytotoxicity side effects, an MEX3B gene expression inhibiting agent that includes the nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic or therapeutic drug for a disease caused by MEX3B gene expression. The present invention is a nucleic acid that is any of (1) to (3): (1) an oligonucleotide that comprises the nucleotide sequence represented by SEQ ID NO: 1 or 2; (2) an antisense oligonucleotide that inhibits expression of the MEX3B gene and that comprises a nucleotide sequence derived by deletion, substitution, and/or addition of one or two nucleotides in the nucleotide sequence represented by SEQ ID NO: 1 or 2; and (3) an antisense oligonucleotide that inhibits expression of the MEX3B gene and that includes the nucleotide sequence represented by SEQ ID NO: 3.

Abstract: A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic or therapeutic agent for disease caused by MEX3B gene expression are provided. This nucleic acid, which inhibits the expression of the MEX3B gene, is an antisense oligonucleotide having a sequence complementary to an oligonucleotide that contains at least 10 contiguous nucleotides in an untranslated region in an exon of the MEX3B gene, or a double-stranded RNA including at least 20 contiguous nucleotides in the aforementioned untranslated region, or DNA encoding said double-stranded RNA.

Abstract: Provided are a method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and an agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5. A method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 having as the index at least one selected from the group consisting of changes in the expression of the MEX3B gene or MEX3B protein and changes in the function of the MEX3B protein.

Abstract: Provided are a refractory asthma prophylactic/therapeutic agent screening method, and a refractory asthma prophylactic/therapeutic agent. This refractory asthma prophylactic/therapeutic agent screening method uses at least one indicator selected from the group consisting of: inhibited activity of the CXCL2 protein or the CXCR2 protein; suppressed expression of the CXCL2 gene or the CXCR2 gene; and suppressed expression of the CXCL2 protein or the CXCR2 protein.

Abstract: A nucleic acid which can inhibit expression of the MEX3B gene with low cytotoxicity as a side effect, an MEX3B gene expression inhibitor which contains said nucleic acid, a method for inhibiting MEX3B gene expression, and a prophylactic or therapeutic agent for disease caused by MEX3B gene expression are provided. This nucleic acid, which inhibits the expression of the MEX3B gene, is an antisense oligonucleotide having a sequence complementary to an oligonucleotide that contains at least 10 contiguous nucleotides in an untranslated region in an exon of the MEX3B gene, or a double-stranded RNA including at least 20 contiguous nucleotides in the aforementioned untranslated region, or DNA encoding said double-stranded RNA.

Abstract: Provided are a method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 and an agent for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5. A method for screening agents for the prevention or treatment of diseases caused by interleukin 6, interleukin 13, TNF, G-CSF, CXCL1, CXCL2, or CXCL5 having as the index at least one selected from the group consisting of changes in the expression of the MEX3B gene or MEX3B protein and changes in the function of the MEX3B protein.